KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Gross Margin: 2009-2025

Historic Gross Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to 51.43%.

  • Teva Pharmaceutical Industries' Gross Margin rose 184.00% to 51.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 50.10%, marking a year-over-year increase of 26.00%. This contributed to the annual value of 48.74% for FY2024, which is 50.00% up from last year.
  • As of Q3 2025, Teva Pharmaceutical Industries' Gross Margin stood at 51.43%, which was up 2.17% from 50.34% recorded in Q2 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Gross Margin peaked at 54.18% during Q4 2023, and registered a low of 43.21% during Q1 2023.
  • Moreover, its 3-year median value for Gross Margin was 48.61% (2024), whereas its average is 48.77%.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' Gross Margin crashed by 443bps in 2022, and later spiked by 861bps in 2023.
  • Teva Pharmaceutical Industries' Gross Margin (Quarterly) stood at 50.00% in 2021, then crashed by 443bps to 45.57% in 2022, then skyrocketed by 861bps to 54.18% in 2023, then crashed by 403bps to 50.15% in 2024, then spiked by 184bps to 51.43% in 2025.
  • Its Gross Margin was 51.43% in Q3 2025, compared to 50.34% in Q2 2025 and 48.24% in Q1 2025.